Search results
Results From The WOW.Com Content Network
Metandienone was formerly approved and marketed as a form of androgen replacement therapy for the treatment of hypogonadism in men, but has since been discontinued and withdrawn in most countries, including in the United States. [ 15][ 4][ 6] It was given at a dosage of 5 to 10 mg/day in men and 2.5 mg/day in women. [ 16][ 17][ 1] v. t.
Treatment of breast cancer in women, although they are now very rarely used for this purpose due to their marked virilizing side effects. [ 43 ] [ 18 ] [ 44 ] In low doses as a component of hormone therapy for postmenopausal and transgender women , for instance to increase energy , well-being , libido , and quality of life , as well as to ...
Hyperandrogenism is a medical condition characterized by high levels of androgens.It is more common in women than men. [4] Symptoms of hyperandrogenism may include acne, seborrhea, hair loss on the scalp, increased body or facial hair, and infrequent or absent menstruation.
Hormone replacement therapy (HRT), also known as menopausal hormone therapy or postmenopausal hormone therapy, is a form of hormone therapy used to treat symptoms associated with female menopause. [ 1 ] [ 2 ] Effects of menopause can include symptoms such as hot flashes , accelerated skin aging, vaginal dryness , decreased muscle mass , and ...
Oxandrolone is an androgen and synthetic anabolic steroid (AAS) medication to help promote weight gain in various situations, to help offset protein catabolism caused by long-term corticosteroid therapy, to support recovery from severe burns, to treat bone pain associated with osteoporosis, to aid in the development of girls with Turner syndrome, and for other indications.
[3] [12] It has strong anabolic effects and weak androgenic effects, which give it a mild side effect profile and make it especially suitable for use in women and children. [3] [12] [13] NPP is a nandrolone ester and a long-lasting prodrug of nandrolone in the body. [3] NPP was first described in 1957 and was introduced for medical use in 1959. [3]
Nandrolone is an agonist of the AR, the biological target of androgens like testosterone and DHT. Unlike testosterone and certain other anabolic steroids, nandrolone is not potentiated in androgenic tissues like the scalp, skin, and prostate, hence deleterious effects in these tissues are lessened. [ 22]
This may result in side effects such as fluid retention and gynecomastia. [3] Like other AAS, nandrolone decanoate has antigonadotropic effects. [3] It has been found to suppress testosterone levels by 57% at a dosage of 100 mg/week and by 70% at a dosage of 300 mg/week in men following 6 weeks of treatment. [3]